Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;9(1):220-224.
doi: 10.21037/jgo.2017.08.14.

Approach and management of checkpoint inhibitor-related immune hepatitis

Aravind Sanjeevaiah  1   2 , Thomas Kerr  3 , Muhammad Shaalan Beg  1   2
Affiliations

Approach and management of checkpoint inhibitor-related immune hepatitis

Aravind Sanjeevaiah et al. J Gastrointest Oncol. 2018 Feb.

Abstract

Immune checkpoint inhibitors have promising clinical activity across multiple gastrointestinal cancers and immune-mediated hepatotoxicity is particularly relevant for this group of patients. In this article we will review the recognition, workup and management of suspected checkpoint inhibitor related immune-hepatitis.

Keywords: Immunotherapy; gastrointestinal cancers; immune checkpoint inhibitors; immune-mediated toxicity.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Workup and management of suspected checkpoint inhibitor related immune hepatotoxicity. AST, aspartate aminotransferase; ALT, alanine aminotransferase; MRI, Magnetic resonance imaging; ULN, upper limit of normal.
See this image and copyright information in PMC

References

    1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23. 10.1056/NEJMoa1003466 - DOI - PMC - PubMed
    1. Administration USFaD. Hematology/Oncology (Cancer) Approvals & Safety Notifications. 2017. Available online: https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm. Accessed 06/21/2017.
    1. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-20. 10.1056/NEJMoa1500596 - DOI - PMC - PubMed
    1. Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717-26. 10.1016/S1470-2045(16)00175-3 - DOI - PubMed
    1. Melero I, Sangro B, Yau TC, et al. Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study. J Clin Oncol 2017;35:226. 10.1200/JCO.2017.35.4_suppl.226 - DOI - PubMed

LinkOut - more resources